Physician profile
Sonja M Roach
NPI 1396770772
$627.43
in general payments reported to CMS, 2019-2025
28 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $91.38 · 2023: $141 · 2024: $146 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $73.95 | 2022-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $71.97 | 2022-2025 | Breztri, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $29.91 | 2022-2024 | Eliquis |
| Baxter Healthcare | $29.50 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Novartis Pharmaceuticals Corporation | $29.40 | 2021-2023 | |
| Medtronic, INC. | $28.97 | 2023-2024 | Intellis Adaptivestim |
| Abbvie INC. | $26.68 | 2021-2025 | |
| Pfizer INC. | $25.61 | 2021 | |
| Amgen INC. | $24.63 | 2021-2024 | Otezla, Repatha |
| Tempus Ai, INC | $24.25 | 2024 | |
| Novavax INC | $20.28 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Collegium Pharmaceutical, INC. | $18.93 | 2025 | Belbuca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.97 | 2025 | |
| Horizon Therapeutics Plc | $16.97 | 2023 | Krystexxa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $16.89 | 2025 | Rexulti |
| Roche Diagnostics Corporation | $15.98 | 2021 | |
| Tactile Systems Technology INC | $15.85 | 2023 | Entre Plus, Flexitouch Plus |
| Neurocrine Biosciences, INC. | $15.78 | 2024 | Ingrezza |
| Cepheid | $15.24 | 2025 | Genexpert |
| Ardelyx, INC. | $14.20 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $13.18 | 2023 | |
| Myovant Sciences INC. | $13.16 | 2022 | |
| Acadia Pharmaceuticals INC | $12.61 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.93 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.46 | 2021 | |
| Organon LLC | $9.13 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.89 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonja Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.